Please assess the completion status of the following clinical trial:

Trial Title: Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of Waldenström's Macroglobulinemia using criteria proposed at 2nd International Workshop on WM, Athens, Greece, 2002.~* Measurable disease, defined as serum monoclonal IgM protein ≥1000 mg/dL by electrophoresis.~* Lymphoplasmacytic infiltration of the bone marrow \>10% involvement.~* Failed at least one, but no more than 3, regimen(s) of prior therapy.~(Please consult with study site for full eligibility criteria)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).